>
BARD1 Life Sciences logo

BD1 - BARD1 Life Sciences Share Price

A$2.59 0.0  0.8%

Last Trade - 1:09am

Sector
Healthcare
Size
Small Cap
Market Cap £114.3m
Enterprise Value £111.0m
Revenue £131k
Position in Universe 632nd / 1908
Bullish
Bearish
Unlock BD1 Revenue
Momentum
Relative Strength (%)
1m -29.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.010 0.000 0.004 0.007 0.009 0.098 +59.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, BARD1Life Sciences Ltd revenues increased from A$46K to A$182K.Net loss increased from A$1.6M to A$3.2M. Revenues reflectan increase in demand for the Company's products andservices due to favorable market conditions. Higher netloss reflects Employee and contractor costs increase fromA$565K to A$1.6M (expense), Research and developmentincrease from A$212K to A$668K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BD1
Graphical History

Revenue

BD1 Revenue Unlock BD1 Revenue

Net Income

BD1 Net Income Unlock BD1 Revenue

Normalised EPS

BD1 Normalised EPS Unlock BD1 Revenue

PE Ratio Range

BD1 PE Ratio Range Unlock BD1 Revenue

Dividend Yield Range

BD1 Dividend Yield Range Unlock BD1 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BD1 EPS Forecasts Unlock BD1 Revenue
Profile Summary

BARD1 Life Sciences Limited is an Australia-based medical diagnostics company. The Company is focused on the development and commercialization of diagnostic solutions for health care professionals and patients. The Company’s technologies include BARD1, hTERT, SIEN-NET and SubB2M. The hTERT is an immunocytochemistry (ICC) assay that detects human telomerase reverse transcriptase (hTERT). The BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins and autoantibodies. The SIEN-NET is a biomarker capture platform that captures and purifies target molecules from patient samples. The SubB2M is a pan-cancer probe that is specific for cancer cells and complements other technologies and biomarkers to detect cancer using a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and positron emission tomography (PET) imaging.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 30, 1983
Public Since April 18, 1991
No. of Shareholders: n/a
No. of Employees: 85
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 79,817,772
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BD1 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BD1
Upcoming Events for BD1
Frequently Asked Questions for BARD1 Life Sciences
What is the BARD1 Life Sciences share price?

As of 1:09am, shares in BARD1 Life Sciences are trading at A$2.59, giving the company a market capitalisation of £114.3m. This share price information is delayed by 15 minutes.

How has the BARD1 Life Sciences share price performed this year?

Shares in BARD1 Life Sciences are currently trading at A$2.59 and the price has moved by 0.243k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BARD1 Life Sciences price has moved by 0.156k% over the past year.

What are the analyst and broker recommendations for BARD1 Life Sciences?

There are no analysts currently covering BARD1 Life Sciences.

When will BARD1 Life Sciences next release its financial results?

BARD1 Life Sciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BARD1 Life Sciences dividend yield?

BARD1 Life Sciences does not currently pay a dividend.

Does BARD1 Life Sciences pay a dividend?

BARD1 Life Sciences does not currently pay a dividend.

When does BARD1 Life Sciences next pay dividends?

BARD1 Life Sciences does not currently pay a dividend.

How do I buy BARD1 Life Sciences shares?

To buy shares in BARD1 Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BARD1 Life Sciences?

Shares in BARD1 Life Sciences are currently trading at A$2.59, giving the company a market capitalisation of £114.3m.

Where are BARD1 Life Sciences shares listed? Where are BARD1 Life Sciences shares listed?

Here are the trading details for BARD1 Life Sciences:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: BD1
What kind of share is BARD1 Life Sciences?

Based on an overall assessment of its quality, value and momentum, BARD1 Life Sciences is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BARD1 Life Sciences share price forecast 2021?

We were not able to load any forecast data for BARD1 Life Sciences.

How can I tell whether the BARD1 Life Sciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BARD1 Life Sciences. Over the past six months, the relative strength of its shares against the market has been 0.206k%. At the current price of A$2.59, shares in BARD1 Life Sciences are trading at 70.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BARD1 Life Sciences PE Ratio?

We were not able to find PE ratio data for BARD1 Life Sciences.

Who are the key directors of BARD1 Life Sciences?

BARD1 Life Sciences's management team is headed by:

Irmgard Irminger-Finger - CSO
Leearne Hinch - CEO
Robert Johnston - DRC
Philip Powell - DRC
Allan Cripps - NID
Peter French - CSO
Geoffrey Cumming - DRC
Who are the major shareholders of BARD1 Life Sciences?

Here are the top five shareholders of BARD1 Life Sciences based on the size of their shareholding:

Merchant Funds Management Pty Ltd Investment Advisor
Percentage owned: 14.54% (11.6m shares)
Moggs Creek Proprietary Ltd. Corporation
Percentage owned: 5.45% (4.36m shares)
Irminger-Finger (Irmgard) Individual Investor
Percentage owned: 5.15% (4.12m shares)
Traoj Pty. Ltd. Corporation
Percentage owned: 1.5% (1.20m shares)
Neate (David) Individual Investor
Percentage owned: 1.38% (1.11m shares)
Similar to BD1
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.